Skip to content

Avidity Biosciences, Inc.

Delisted

CIK 1599901fmd_0KQN282G49VKPA61SR304F2E7KManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2018 to Dec 31, 2025, 29 periods

Latest annual · FY2025

Millions
Total revenues
19
Operating income
(746)
Net income
(685)
Free cash flow
(664)

Latest quarter · Q4 FY2025

Millions
Total revenues
1
Operating income
(254)
Net income
(237)
Free cash flow
(175)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2022 to FY2025
+26.7%
Revenue, 5 yearsFY2020 to FY2025
+22.5%
Net income, 5 yearsFY2020 to FY2025
n/m

Avidity Biosciences, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2025FY2024ChangeSource
Revenue$18.8 million$10.9 million+72.1%10-K 2026-02-23 · proof
Operating income-$745.9 million-$378.9 million10-K 2026-02-23 · proof
Net income-$684.6 million-$322.3 million10-K 2026-02-23 · proof
Cash from operating activities-$650.4 million-$300.9 million10-K 2026-02-23 · proof
Free cash flow-$663.8 million-$307.9 million10-K 2026-02-23 · proof
Total assets$2 billion$1.6 billion+25.2%10-K 2026-02-23 · proof
Total liabilities$269.5 million$138.9 million+93.9%10-K 2026-02-23 · proof
Cash and cash equivalents$382.5 million$219.9 million+74%10-K 2026-02-23 · proof
What was Avidity Biosciences, Inc.'s revenue in fiscal 2025?
Avidity Biosciences, Inc. reported revenue of $18.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $10.9 million the year before (+72.1%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What was Avidity Biosciences, Inc.'s operating income in fiscal 2025?
Avidity Biosciences, Inc. reported operating income of -$745.9 million for fiscal 2025 (the year ended Dec 31, 2025), against -$378.9 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What was Avidity Biosciences, Inc.'s net income in fiscal 2025?
Avidity Biosciences, Inc. reported net income of -$684.6 million for fiscal 2025 (the year ended Dec 31, 2025), against -$322.3 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What was Avidity Biosciences, Inc.'s cash from operating activities in fiscal 2025?
Avidity Biosciences, Inc. reported cash from operating activities of -$650.4 million for fiscal 2025 (the year ended Dec 31, 2025), against -$300.9 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What was Avidity Biosciences, Inc.'s free cash flow in fiscal 2025?
Avidity Biosciences, Inc. reported free cash flow of -$663.8 million for fiscal 2025 (the year ended Dec 31, 2025), against -$307.9 million the year before. Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What are Avidity Biosciences, Inc.'s total assets?
As of Dec 31, 2025, Avidity Biosciences, Inc. reported total assets of $2 billion, against $1.6 billion a year earlier (+25.2%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What are Avidity Biosciences, Inc.'s total liabilities?
As of Dec 31, 2025, Avidity Biosciences, Inc. reported total liabilities of $269.5 million, against $138.9 million a year earlier (+93.9%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC
What are Avidity Biosciences, Inc.'s cash and cash equivalents?
As of Dec 31, 2025, Avidity Biosciences, Inc. reported cash and cash equivalents of $382.5 million, against $219.9 million a year earlier (+74%). Source: the 10-K filed with the SEC on Feb 23, 2026. SEC

Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1599901&period_type=annual&limit=5"

Information only, not investment advice.